All Articles

Lung cancer is the top cause of cancer death and the third most common cancer type in the United States, according to the National Cancer Institute. With an estimated 234,580 new cases of lung and bronchus cancer to be diagnosed in 2024 alone, this cancer will almost certainly affect a portion of your patients. Test your knowledge of this disease here.

Breast cancer is the second most common cancer among women after skin cancer, according to the National Cancer Institute. In fact, in 2024 an estimated 310,720 cases will be diagnosed in women, representing 15.5% of all new cancers diagnosed that year, and 42,250 women with breast cancer will die. Test your knowledge of this widespread cancer.

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses updated data from the phase 1a/1b trial of zongertinib in patients with HER2 aberration-positive solid tumors. In this video, she reports data from phase 1b, the ongoing dose expansion phase, which includes patients with HER2 mutation–positive NSCLC and focuses on nursing considerations for managing adverse events.

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation.

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations.

Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications.

The Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path is a resource that oncology nurses and navigators can use to assist patients and caregivers in the fight against early-stage breast cancer. Oncology nurses and navigators guide patients through their treatment journey from time of diagnosis into survivorship, providing education, resources, and support.